This week on Tech Can’t Save Us, host Paul David is joined by Erin Lee, CEO of Flow Neuroscience, the Swedish health-tech company behind a breakthrough in depression treatment: a wearable brain-stimulation headset that offers a safe, evidence-based alternative to traditional antidepressants.

Flow’s device uses transcranial direct current stimulation (tDCS) to gently activate brain regions responsible for mood regulation. In a landmark 2023 double-blind, placebo-controlled trial, Flow outperformed 21 frontline antidepressants, earning a feature in Nature’s “Future of Medicine” edition, an unprecedented milestone for at-home neuroscience technology. Today, Flow has 50,000+ users, is available across 200 clinics and multiple NHS trusts, and has raised nearly $20M to bring new forms of treatment to those who need it most.

Erin shares how the Flow experience works day-to-day, why users often see improvements within the first two weeks, and how pairing brain stimulation with an app-driven behavioral toolkit increases neuroplasticity and supports long-term recovery. She also speaks candidly about public perception, clinician adoption, and why Flow chose the harder, highly regulated path to build trust and clinical credibility from day one.

The conversation expands into Flow’s growth strategy, upcoming global expansion, and Erin’s transition from leadership roles at Google, Uber, and Babylon Health into one of the most personal and emotionally charged spaces in healthcare. She reflects on the influence of her own family’s mental health history, the importance of scientific rigor, and what it means to build a startup where the mission is literally life-changing.

Find more about Flow Neuroscience here: https://www.flowneuroscience.com
Follow Erin on LinkedIn: https://www.linkedin.com/in/erinslee/

Ver todos los episodios